On December 17, 2021, CM Life Sciences III Inc., a Delaware corporation (“CMLS III”) consummated the previously announced business combination pursuant to the terms of the Agreement and Plan of Merger, dated as of August 5, 2021, as amended September 21, 2021 and October 28, 2021, by and among CMLS III, Clover III Merger Sub, Inc., a Delaware corporation and EQRx, Inc. (“Old EQRx”). Upon the consummation of the Transactions, and in accordance with the terms of the Merger Agreement, each director (except Eli Casdin and Amy Abernethy) and executive officer of CMLS III ceased serving in such capacities and nine new directors were appointed to the Board. The Board was divided into three staggered classes of directors and each director was assigned to one of the three classes.

At each annual meeting of the stockholders, a class of directors will be elected for a three-year term to succeed the directors of the same class whose terms are then expiring. The terms of the directors will expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the year 2022 for Class I directors, 2023 for Class II directors and 2024 for Class III directors. Paul Berns, Jorge Conde and Sandra Horning were appointed as Class I directors; Samuel Merksamer, Clive Meanwell, Krishna Yeshwant and Kathryn Giusti were appointed as Class II directors; and Alexis Borisy, Eli Casdin, Melanie Nallicheri and Amy Abernethy were appointed as Class III directors.

Furthermore, following the consummation of the Transactions, the Board established four standing committees: an audit committee, a compensation and talent development committee, a nominating and corporate governance committee and a research and development committee. The members of audit committee are Paul Berns, Eli Casdin and Samuel Merksamer, and Eli Casdin serves as the chairperson of the audit committee. The members of the compensation and talent development committee are Jorge Conde, Sandra Horning and Krishna Yeshwant, and Krishna Yeshwant is the chairperson of the compensation and talent development committee.

The members of the nominating and corporate governance committee are Paul Berns, Eli Casdin, Kathryn Giusti and Clive Meanwell, and Paul Berns is the chairperson of the nominating and corporate governance committee. The members of the research and development committee are Amy Abernethy, Sandra Horning, Clive Meanwell and Krishna Yeshwant, and Sandra Horning is the chairperson of the research and development committee.